NCT03288025Active, not recruiting
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 19 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to investigate the extent to which diet and exercise may improve PAH through the modulation of insulin sensitivity. The central hypothesis is that dysregulated glucose metabolism elicits a response in PAH patients that can be modified by exercise and diet, thereby leading to improvements in pulmonary vascular disease.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 34 (actual)
- First submitted
- 31 Aug 2017
- Start date
- 27 Sept 2017
- Primary completion date
- 18 Feb 2022
- Lead sponsor
- The Cleveland Clinic
- NCT number
- NCT03288025
What you commit to
- Study type: Interventional
- Participants enrolled: 34
- From 27 Sept 2017 to the primary completion date, 18 Feb 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Syncope within the previous 3 months
Other illness
- Decompensated Right Heart Failure
- Cardiac Arrhythmia (except for controlled atrial fibrillation or flutter)
- Portal Hypertension
- Pulmonary hypertension due to Lung Disease and Hypoxia
- Pulmonary Hypertension due to Left Heart Disease
- Chronic Thromboembolic Pulmonary Hypertension
- Pulmonary Hypertension associated with systemic diseases such as hematological disorders and sarcoidosis
- Type 2 Diabetes
- Evidence of cardiac ischemia on a graded exercise test
Other
- NYHA Class IV
- Baseline supplemental O2 \> 4 LPM
Who the study is looking for
- Age range between 18-75 years old
- Group 1 PAH, including idiopathic, heritable, drugs and toxin induced, and PAH associated with connective tissue disease, HIV infection and congenital heart disease
- NYHA Class II or III
- ≥ 1 PAH-targeted therapy with a stable dose for ≥ 2 months
- Stable dose of diuretics and rate of supplemental oxygen for the preceding 2 months
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cleveland Clinic Foundation Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.